Ad
related to: theophylline therapeutic use in adults with dementia research report printable
Search results
Results from the WOW.Com Content Network
Theophylline's first clinical use came in 1902 as a diuretic. [35] It took an additional 20 years until it was first reported as an asthma treatment. [ 36 ] The drug was prescribed in a syrup up to the 1970s as Theostat 20 and Theostat 80, and by the early 1980s in a tablet form called Quibron.
Phosphodiesterase-5. A phosphodiesterase inhibitor is a drug that blocks one or more of the five subtypes of the enzyme phosphodiesterase (PDE), thereby preventing the inactivation of the intracellular second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) by the respective PDE subtype(s).
Alzheimer's Research UK (ARUK) is a dementia research charity in the United Kingdom, founded in 1992 as the Alzheimer's Research Trust. ARUK funds scientific studies to find ways to treat, cure or prevent all forms of dementia, including Alzheimer's disease , vascular dementia , dementia with Lewy bodies and frontotemporal dementia .
Pre-dementia or early-stage dementia (stages 1, 2, and 3). In this initial phase, a person can still live independently and may not exhibit obvious memory loss or have any difficulty completing ...
The therapeutic index (TI; also referred to as therapeutic ratio) is a quantitative measurement of the relative safety of a drug with regard to risk of overdose. It is a comparison of the amount of a therapeutic agent that causes toxicity to the amount that causes the therapeutic effect . [ 1 ]
The prevention of dementia involves reducing the number of risk factors for the development of dementia, and is a global health priority needing a global response. [1] [2] Initiatives include the establishment of the International Research Network on Dementia Prevention (IRNDP) [3] which aims to link researchers in this field globally, and the establishment of the Global Dementia Observatory ...
Diphenhydramine is the primary constituent of dimenhydrinate and dictates the primary effect. The main differences relative to pure diphenhydramine are a lower potency due to being combined with 8-chlorotheophylline (by weight, dimenhydrinate is between 53% and 55.5% diphenhydramine) [10] and the fact that the stimulant properties of 8-chlorotheophylline help reduce the side ...
In animal and human studies, it has shown similar efficacy to theophylline but with significantly fewer side effects. [5] In February 2014, the US FDA granted an orphan drug designation to doxofylline for the treatment of bronchiectasis following the submission of an application by Alitair Pharmaceuticals, in May 2013. [6] [7] [8]
Ad
related to: theophylline therapeutic use in adults with dementia research report printable